Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for
the treatment of type 2 diabetes (T2D). In this 56-week, open-label study, 813 adults
with T2D inadequately controlled on 1 to 2 oral antidiabetic drugs (OADs; metformin,
sulfonylurea, thiazolidinediones) were randomized 1:1 to once-weekly semaglutide 1.0 mg
or once-weekly exenatide extended release (ER) 2.0 mg. Primary endpoint was change
in glycated hemoglobin (HbA1c) from baseline to Week 56.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
